Clinical Outcomes of Patients With Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated With Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

Oncologist - United States
doi 10.1634/theoncologist.2018-0618
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

P012 Patients With Cancer and Preexisting Autoimmune and Inflammatory Diseases Treated by Anti-Programmed Death 1 (PD-1) Antibodies at Gustave Roussy Cancer Center

2019English

Clinical Significance of Soluble Programmed Cell Death-1 and Soluble Programmed Cell Death-Ligand 1 in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

PLoS ONE
Multidisciplinary
2019English

Real‐World Outcomes of Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

Oncologist
Cancer ResearchMedicineOncology
2018English

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

JAMA Dermatology
DermatologyMedicine
2016English

Predictive Role of Computed Tomography Texture Analysis in Patients With Metastatic Urothelial Cancer Treated With Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors

European urology oncology
OncologyRadiologyUrologyNuclear MedicineImagingSurgery
2019English

Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients With Advanced Melanoma Treated With Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical Trial

European Journal of Cancer
Cancer ResearchOncology
2018English

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer

Open Forum Infectious Diseases
OncologyNeurology
2018English

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinicopathological Features Predict Outcomes in Patients With Radioiodine‐Refractory Differentiated Thyroid Cancer Treated With Sorafenib: A Real‐World Study

Oncologist
Cancer ResearchMedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy